Profile data is unavailable for this security.
About the company
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
- Revenue in USD (TTM)6.16m
- Net income in USD-25.58m
- Incorporated2015
- Employees15.00
- LocationCervoMed Inc20 Park Plaza, Suite 424BOSTON 02116United StatesUSA
- Phone+1 (617) 744-4400
- Fax+1 (434) 220-0722
- Websitehttps://cervomed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NextCure Inc | 0.00 | -58.01m | 33.55m | 43.00 | -- | 1.42 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Outlook Therapeutics Inc | 297.49k | -102.86m | 35.05m | 17.00 | -- | -- | -- | 117.83 | -2.71 | -2.71 | 0.0068 | -0.5971 | 0.0169 | 0.4221 | -- | 17,499.41 | -583.70 | -240.08 | -- | -- | -57.80 | -- | -34,576.16 | -22,354.50 | 0.2795 | -151.67 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -49.89m | 35.36m | 22.00 | -- | 1.39 | -- | 707.17 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 35.40m | 38.00 | 2.24 | -- | 1.33 | 0.233 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.56m | 37.00 | -- | 2.58 | -- | 395.15 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| CervoMed Inc | 6.16m | -25.58m | 35.99m | 15.00 | -- | 1.38 | -- | 5.84 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.24m | 24.00 | -- | 3.49 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.53m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 36.86m | 52.00 | -- | 10.01 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 37.15m | 10.00 | -- | 1.33 | -- | 9.23 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 37.60m | 14.00 | -- | 1.63 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 37.78m | 64.00 | -- | 3.26 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 38.19m | 16.00 | -- | 2.97 | -- | 47.86 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 38.34m | 46.00 | -- | 0.5772 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
Data as of Mar 03 2026. Currency figures normalised to CervoMed Inc's reporting currency: US Dollar USD
20.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AWM Investment Co., Inc.as of 31 Dec 2025 | 794.63k | 8.59% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 470.63k | 5.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 316.20k | 3.42% |
| Geode Capital Management LLCas of 31 Dec 2025 | 65.88k | 0.71% |
| Millennium Management LLCas of 31 Dec 2025 | 60.27k | 0.65% |
| Citadel Securities LLCas of 31 Dec 2025 | 48.62k | 0.53% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 48.07k | 0.52% |
| Clarfeld Financial Advisors LLCas of 31 Dec 2025 | 37.48k | 0.41% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 36.15k | 0.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 30.65k | 0.33% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
